AbbVie Stock: Buy, Sell, or Hold in October?

AbbVie, a pharmaceutical giant with 53 consecutive years of dividend increases, remains a stable long-term investment despite losing U.S. patent exclusivity for its blockbuster drug Humira in 2023. The company has offset this decline through new immunology drugs (Skyrizi and Rinvoq) and strategic acquisitions including Allergan (Botox). Analysts project 9% revenue CAGR and 21% adjusted EPS CAGR from 2025-2028. At $264 per share with a 2.6% forward yield and 16x forward P/E, the stock is reasonably valued for buy-and-hold investors.